Kiera Fallon
Research Associate II at CRISPR Therapeutics | Boston, Massachusetts, United States
Kiera Fallon’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Research Associate II at CRISPR Therapeutics in June 2024 - Present
Business Development Representative at Sannova Analytical in January 2024 - November 2024
Reseach Associate II at Beam Therapeutics in June 2022 - November 2023
Boston University, Master of Business Administration - MBA, August 2026
University of Massachusetts Amherst, Bachelor of Science - BS, August 2026
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Discover more about CRISPR TherapeuticsClinical Trial Manager at CRISPR Therapeutics
Clinical Trial Manager at CRISPR Therapeutics
(August 2025 – Present)
Cell Therapy at CRISPR Therapeutics || MBA Candidate at WPI
Cell Therapy at CRISPR Therapeutics
(July 2023 – Present)
Senior Vice President Finance
Senior Vice President Finance at CRISPR Therapeutics
(January 2025 – Present)
Scientist at CRISPR Therapeutics
Scientist, CRISPR-X at CRISPR Therapeutics
(June 2024 – Present)
Executive Director, Head of In Vivo Research | Immuno-Oncology | Cell and Gene Therapy | CRISPR | LNP Delivery | CAR-T | CTA and IND Strategy | Cross-Functional Leadership | Regulatory Interactions | AAV | Liver | Eye |
Head of In Vivo Research, Executive Director, and Immuno-Oncology Lead at CRISPR Therapeutics
(July 2024 – Present)
Senior Director at CRISPR Therapeutics
Senior Director, CRISPR-X at CRISPR Therapeutics
(Jul 2025 – Present)
What is Kiera Fallon email address?
Email Kiera Fallon at [email protected] and [email protected]. This email is the most updated Kiera Fallon's email found in 2026.
How to contact Kiera Fallon?
To contact Kiera Fallon send an email to [email protected] or [email protected]. (updated on July 2026)
What company does Kiera Fallon work for?
Kiera Fallon works for CRISPR Therapeutics.
What is Kiera Fallon's role at CRISPR Therapeutics?
Kiera Fallon is Research Associate II
What industry does Kiera Fallon work in?
Kiera Fallon works in the Biotechnology industry.